Compare ATOS & PCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATOS | PCM |
|---|---|---|
| Founded | 2009 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 82.0M |
| IPO Year | 2012 | N/A |
| Metric | ATOS | PCM |
|---|---|---|
| Price | $0.82 | $6.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.33 | N/A |
| AVG Volume (30 Days) | ★ 911.6K | 29.1K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.68% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $6.88 |
| 52 Week High | $1.29 | $10.20 |
| Indicator | ATOS | PCM |
|---|---|---|
| Relative Strength Index (RSI) | 51.07 | 42.71 |
| Support Level | $0.68 | $6.19 |
| Resistance Level | $0.99 | $6.27 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 44.30 | 38.10 |
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.